ILMN
Price
$139.04
Change
+$0.39 (+0.28%)
Updated
Jan 7, 04:59 PM (EDT)
29 days until earnings call
MYGN
Price
$14.30
Change
+$0.52 (+3.77%)
Updated
Jan 7, 04:59 PM (EDT)
55 days until earnings call
Ad is loading...

ILMN vs MYGN

Header iconILMN vs MYGN Comparison
Open Charts ILMN vs MYGNBanner chart's image
Illumina
Price$139.04
Change+$0.39 (+0.28%)
Volume$22.3K
CapitalizationN/A
Myriad Genetics
Price$14.30
Change+$0.52 (+3.77%)
Volume$10.27K
CapitalizationN/A
ILMN vs MYGN Comparison Chart
Loading...
ILMN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MYGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ILMN vs. MYGN commentary
Jan 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ILMN is a Hold and MYGN is a Buy.

Ad is loading...
COMPARISON
Comparison
Jan 08, 2025
Stock price -- (ILMN: $139.08 vs. MYGN: $14.30)
Brand notoriety: ILMN: Notable vs. MYGN: Not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: ILMN: 61% vs. MYGN: 74%
Market capitalization -- ILMN: $21.09B vs. MYGN: $1.93B
ILMN [@Medical Specialties] is valued at $21.09B. MYGN’s [@Medical Specialties] market capitalization is $1.93B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ILMN’s FA Score shows that 0 FA rating(s) are green whileMYGN’s FA Score has 1 green FA rating(s).

  • ILMN’s FA Score: 0 green, 5 red.
  • MYGN’s FA Score: 1 green, 4 red.
According to our system of comparison, both ILMN and MYGN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ILMN’s TA Score shows that 5 TA indicator(s) are bullish while MYGN’s TA Score has 4 bullish TA indicator(s).

  • ILMN’s TA Score: 5 bullish, 4 bearish.
  • MYGN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ILMN is a better buy in the short-term than MYGN.

Price Growth

ILMN (@Medical Specialties) experienced а +4.08% price change this week, while MYGN (@Medical Specialties) price change was +4.30% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +4.42%. For the same industry, the average monthly price growth was +3.87%, and the average quarterly price growth was +2.97%.

Reported Earning Dates

ILMN is expected to report earnings on Apr 29, 2025.

MYGN is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Medical Specialties (+4.42% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ILMN($21.1B) has a higher market cap than MYGN($1.93B). MYGN YTD gains are higher at: 4.303 vs. ILMN (4.078). MYGN has higher annual earnings (EBITDA): -197.4M vs. ILMN (-608M). ILMN has more cash in the bank: 1.05B vs. MYGN (141M). MYGN has less debt than ILMN: MYGN (152M) vs ILMN (2.26B). ILMN has higher revenues than MYGN: ILMN (4.5B) vs MYGN (753M).
ILMNMYGNILMN / MYGN
Capitalization21.1B1.93B1,095%
EBITDA-608M-197.4M308%
Gain YTD4.0784.30395%
P/E Ratio49.50N/A-
Revenue4.5B753M598%
Total Cash1.05B141M748%
Total Debt2.26B152M1,488%
FUNDAMENTALS RATINGS
ILMN vs MYGN: Fundamental Ratings
ILMN
MYGN
OUTLOOK RATING
1..100
218
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
95
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9794
PRICE GROWTH RATING
1..100
4891
P/E GROWTH RATING
1..100
941
SEASONALITY SCORE
1..100
3824

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ILMN's Valuation (75) in the Biotechnology industry is in the same range as MYGN (95). This means that ILMN’s stock grew similarly to MYGN’s over the last 12 months.

ILMN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MYGN (100). This means that ILMN’s stock grew similarly to MYGN’s over the last 12 months.

MYGN's SMR Rating (94) in the Biotechnology industry is in the same range as ILMN (97). This means that MYGN’s stock grew similarly to ILMN’s over the last 12 months.

ILMN's Price Growth Rating (48) in the Biotechnology industry is somewhat better than the same rating for MYGN (91). This means that ILMN’s stock grew somewhat faster than MYGN’s over the last 12 months.

MYGN's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for ILMN (94). This means that MYGN’s stock grew significantly faster than ILMN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ILMNMYGN
RSI
ODDS (%)
Bullish Trend 1 day ago
70%
Bullish Trend 1 day ago
76%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
77%
Momentum
ODDS (%)
Bullish Trend 1 day ago
70%
Bullish Trend 1 day ago
66%
MACD
ODDS (%)
Bullish Trend 1 day ago
63%
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
68%
Bullish Trend 1 day ago
72%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 1 day ago
70%
Bullish Trend 1 day ago
74%
Declines
ODDS (%)
Bearish Trend 20 days ago
81%
Bearish Trend 12 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
79%
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
78%
View a ticker or compare two or three
Ad is loading...
ILMN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MYGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FLMIX9.49N/A
N/A
Meeder Muirfield Institutional
AIGGX15.57N/A
N/A
Aristotle Growth Equity I-2
FWBTX14.25-0.11
-0.77%
Fidelity Advisor Multi-Asset Income C
MIGIX17.69-0.24
-1.34%
Morgan Stanley Inst Global Insgt I
ALLIX109.83-1.92
-1.72%
AB Large Cap Growth I

ILMN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ILMN has been loosely correlated with RVTY. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ILMN jumps, then RVTY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ILMN
1D Price
Change %
ILMN100%
+0.31%
RVTY - ILMN
53%
Loosely correlated
+0.87%
VCYT - ILMN
48%
Loosely correlated
-2.12%
BIO - ILMN
48%
Loosely correlated
+0.15%
A - ILMN
44%
Loosely correlated
+0.72%
PACB - ILMN
44%
Loosely correlated
+0.50%
More

MYGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, MYGN has been loosely correlated with WAT. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if MYGN jumps, then WAT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MYGN
1D Price
Change %
MYGN100%
+3.77%
WAT - MYGN
39%
Loosely correlated
-0.02%
GMED - MYGN
36%
Loosely correlated
-0.57%
TMO - MYGN
35%
Loosely correlated
+1.57%
VCYT - MYGN
35%
Loosely correlated
-2.12%
QDEL - MYGN
35%
Loosely correlated
-1.47%
More